GlassScriptPhysician profile
Marc L Weitzman
NPI 1558465807
$3,543.36
in general payments reported to CMS, 2019-2025
23 companies · $852 in 2025
The $852 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $439 · 2021: $344 · 2022: $511 · 2023: $549 · 2024: $588 · 2025: $852.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,901 · Education: $87.83.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,901.14 |
| Education | $87.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,068.67 | 2022-2025 | Durysta, Xen Glaucoma Treatment System, Alphagan P |
| Allergan, INC. | $440.77 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $315.80 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Alcon Vision LLC | $308.18 | 2019-2025 | Rocklatan, Tryptyr, Dailies Total1 |
| Sun Pharmaceutical Industries INC. | $257.82 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $202.66 | 2024-2025 | Xdemvy |
| Mallinckrodt Hospital Products INC. | $184.36 | 2021-2025 | Acthar |
| Sight Sciences, INC. | $139.77 | 2019-2020 | |
| Aerie Pharmaceuticals, INC. | $124.64 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $99.79 | 2019-2023 | |
| Dompe US, INC. | $76.05 | 2024-2025 | Oxervate |
| Amgen INC. | $54.42 | 2024-2025 | Tepezza |
| Oyster Point Pharma, INC. | $45.30 | 2023-2024 | Tyrvaya |
| Shire North American Group INC | $36.56 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $34.05 | 2020-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $26.08 | 2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Eyepoint US, INC. | $24.29 | 2020 | |
| Thea Pharma INC. | $22.10 | 2024 | Iyuzeh |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Eyevance Pharmaceuticals LLC | $18.66 | 2021 | |
| Biotissue Holdings INC. | $17.00 | 2022 | |
| Ocular Therapeutix, INC. | $14.97 | 2021 | |
| Johnson & Johnson Surgical Vision, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marc Weitzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.